Considerable progress was achieved in the field of mesothelioma (MPM) research and treatment over the last decades. However, high local recurrence rates e even after aggressive treatment -remain an unresolved problem. Based on anatomic constraints, it is impossible to leave adequate safety margins -usually required for oncological surgery -when resecting mesothelioma, therefore leading to only macroscopic e but not microscopic -complete resection (MCR). The remaining microscopically small tumor residuals are most probably the origin of later recurrence. Intracavitary local treatment modalities target this hypothesis. Substances can be applied locally in desired high doses, while side effects can be reduced by decreased systemic absorption. Several intracavitary approaches have been evaluated to try to reduce local recurrence and were mostly applied after MCR, either lung sparing (extended) pleurectomy / decortication ((e)P/D) or extrapleural pneumonectomy (EPP). Intracavitary chemotherapy has been successfully applied in peritoneal carcinomatosis 1-4 and the knowledge gained transferred to MPM because of certain similarities of both tumors. Adding hyperthermia to the concept is based on the principle that hypothermia leads to increased penetration depth of the chemotherapeutic agent into the tissue and therefore a maximized cytotoxic effect on tumor cells. Looking at current guidelines, intracavitary treatments have not yet entered routine treatment regimens for mesothelioma patients. The recommendation of the American Society of Clinical Oncology Clinical Practice Guideline (ASCO) 5 summarizes: Intracavitary therapies (chemotherapy or photodynamic therapy) may be administered safely in experienced centers of excellence, preferably in the context of a clinical trial. Their role in improving outcome is indeterminate (Type of recommendation: evidence based; Evidence quality: low; Strength of recommendation: weak). Hyperthermic intraoperative chemotherapy (HIOC) with cisplatin has demonstrated safety and some efficacy in two phase I or II prospective clinical trials in patients undergoing EPP and P/D immediately after surgery 6, 7 . A safe maximally tolerated dose and the methoogy to reduce associated complications have been established (table 1) . Another technique to reduce systemic side effects and simultaneously increase the local concentration of the drug is to combine cisplatin with a fibrin glue. Cisplatin-fibrin can be sprayed on the resection surface of the chest wall and the lung after surgery (figure 1) 8 .The pharmacokinetic advantages and efficacy to reduce tumor recurrence have been demonstrated in several preclinical studies 9-11 . In a phase I dose escalation trial (INFLuenCe-Meso) safety was confirmed, and currently further tested in a phase II clinical trial (NCT01644994). Addionally to intracavitary applied chemotherapeutics which are mainly platinum based other substances were tested. Tada et al recently published the results of a phase I clinical trial using zoledronic acid 12 . This intrapleuraly applied drug is a third generation bisphosphonate and was used in patients with inoperable MPM. Prior to this, the efficacy was equally demonstrated in preclinical studies 12, 13 (Table) , with prolonged duration of responses reported. In combination, nivolumab and ipilimumab has a disease control rate (DCR) at 12 weeks of 50%, and the combination of durvalumab and tremelimumab had response rate of 28%. In combination with chemotherapy durvalumab, pemetrexed and cisplatin had a 65% 6 month progression free survival and 55% response rate (Table) . While these results are encouraging, the majority of reported trials are small, single arm, with response or disease control rates as the primary endpoints. The only randomized control trial to have been completed so far, evaluated tremelimumab as a single agent in patients with previously treated mesothelioma following encouraging results from two single arm single institution studies of tremelimumab (9). Unfortunately, the primary endpoint of OS was not met (tremelimumab vs. placebo median OS 7.7 months vs. 7.3 months (0$92 [95% CI 0$76À1$12], p¼0$41). It is notable that the DCR on the placebo arm (defined as CR, PR or SD of at least 12 weeks) was 21$7% (16$0e28$3) highlighting some patients have indolent disease and the need for randomized trials comparing with standard of care. 
